Search
for
Sort by
Research 61–90 of 1000+
- Herpes zoster ophthalmicus (HZO) secondary to platelet-rich plasma (PRP) therapy - A case report
- Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
- Severe Acute Respiratory Syndrome Among Children
- Sub-acute cutaneous lupus erythematosus following nitrofurantoin: causative or coincidental?
- PD57-09 NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM SURGICAL RISK CALCULATOR POORLY PREDICTS COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY WITH URINARY DIVERSION: THE CASE FOR A PROCEDURE-SPECIFIC RISK CALCULATOR
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- Adverse Effects and Drug Interactions of Biologic Agents
- Posters Presented at the 19th Joint Meeting of the International Society of Dermatopathology, March 2–3, 2016, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia, USA
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- New developments in the treatment of systemic lupus erythematosus
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Alopecia areata: current concepts
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 10 Complications Associated with PRP and Microneedling in Aesthetic Medicine
- Malassezia spp. Overgrowth in a Chinchilla Cat
- Botulinum toxin: Pearls & pitfalls
- C002 Vasculitis: A differential diagnostic approach
- Mucocutaneous side effects of antineoplastic chemotherapy
- Cutaneous drug reactions
- Injectable Ag nanoclusters-based hydrogel for wound healing via eliminating bacterial infection and promoting tissue regeneration
- Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series
- Androgens in SARS-CoV-2 Coronavirus Infections